Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

$24.99

DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Two-Component Disaggregation of ROE

Vertex Pharmaceuticals Inc., decomposition of ROE

Microsoft Excel
ROE = ROA × Financial Leverage
Dec 31, 2025 = ×
Dec 31, 2024 = ×
Dec 31, 2023 = ×
Dec 31, 2022 = ×
Dec 31, 2021 = ×

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The period under review demonstrates fluctuating financial performance, particularly concerning profitability and its relationship to financial leverage. Return on Assets (ROA) initially increased before experiencing a significant decline, followed by a partial recovery. Return on Equity (ROE) mirrored this pattern, exhibiting a similar trajectory of growth, decline, and subsequent improvement. Financial Leverage remained relatively stable throughout the observed timeframe.

Return on Assets (ROA)
ROA increased from 17.44% in 2021 to 18.30% in 2022, indicating improved asset utilization efficiency. However, a substantial decrease was observed in 2023, with ROA falling to 15.92%. This downward trend continued into 2024, resulting in a negative ROA of -2.38%. A recovery was then noted in 2025, with ROA rising to 15.42%, though it did not reach the levels observed in 2021 and 2022.
Financial Leverage
Financial Leverage remained consistently around 1.3, with a slight decrease from 1.33 in 2021 to 1.30 in 2022 and 1.29 in 2023. A minor increase to 1.37 was seen in 2024, which was maintained in 2025. This suggests a relatively stable capital structure and consistent use of debt financing throughout the period.
Return on Equity (ROE)
ROE followed a similar pattern to ROA, increasing from 23.19% in 2021 to 23.88% in 2022. The decline in ROA translated to a decrease in ROE, falling to 20.59% in 2023. A significant drop occurred in 2024, with ROE becoming negative at -3.26%. ROE recovered in 2025, reaching 21.18%, but remained below the levels seen in the earlier years of the period. The consistent financial leverage suggests that changes in ROE are primarily driven by fluctuations in ROA.

The negative ROA and ROE in 2024 represent a period of significant underperformance. While a recovery is evident in 2025, the levels remain below those achieved in 2021 and 2022. The stability of financial leverage indicates that the observed fluctuations in profitability are not attributable to changes in the company’s capital structure, but rather to operational efficiency or external factors impacting asset returns.


Three-Component Disaggregation of ROE

Vertex Pharmaceuticals Inc., decomposition of ROE

Microsoft Excel
ROE = Net Profit Margin × Asset Turnover × Financial Leverage
Dec 31, 2025 = × ×
Dec 31, 2024 = × ×
Dec 31, 2023 = × ×
Dec 31, 2022 = × ×
Dec 31, 2021 = × ×

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The period under review demonstrates fluctuating performance as measured by the three-component DuPont analysis. Return on Equity (ROE) experienced volatility, influenced by shifts in Net Profit Margin, Asset Turnover, and Financial Leverage. A notable decline in ROE occurred in 2024, followed by a recovery in 2025.

Net Profit Margin
Net Profit Margin increased from 30.92% in 2021 to 37.20% in 2022, indicating improved profitability. It remained relatively stable at 36.68% in 2023 before experiencing a substantial decrease to -4.86% in 2024. A recovery to 32.94% was observed in 2025, though not reaching prior levels. This suggests potential operational challenges or unusual items impacting earnings in 2024.
Asset Turnover
Asset Turnover exhibited a consistent downward trend from 0.56 in 2021 to 0.43 in 2023, suggesting decreasing efficiency in utilizing assets to generate revenue. A slight increase to 0.49 in 2024 was followed by a further decrease to 0.47 in 2025. This indicates a continued struggle to improve asset utilization.
Financial Leverage
Financial Leverage remained relatively stable between 1.30 and 1.33 from 2022 to 2025, with a slight increase to 1.37 in 2024. This indicates a consistent level of debt financing relative to equity, with a minor uptick in 2024. The stability suggests a deliberate capital structure management approach.

The decline in ROE in 2024 is primarily attributable to the negative Net Profit Margin, despite a slight increase in Financial Leverage and Asset Turnover. The recovery in ROE in 2025 is linked to the improvement in Net Profit Margin, partially offset by continued declines in Asset Turnover. The consistent, though decreasing, Asset Turnover suggests a potential area for operational improvement. Overall, the company’s profitability appears to be the primary driver of ROE fluctuations during this period.


Five-Component Disaggregation of ROE

Vertex Pharmaceuticals Inc., decomposition of ROE

Microsoft Excel
ROE = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Financial Leverage
Dec 31, 2025 = × × × ×
Dec 31, 2024 = × × × ×
Dec 31, 2023 = × × × ×
Dec 31, 2022 = × × × ×
Dec 31, 2021 = × × × ×

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The five-component DuPont analysis reveals significant fluctuations in performance metrics between 2021 and 2025. Return on Equity (ROE) experienced volatility, beginning at 23.19% in 2021, peaking at 23.88% in 2022, declining to 20.59% in 2023, plummeting to -3.26% in 2024, and recovering to 21.18% in 2025. This ROE trajectory is largely explained by shifts in the underlying components, particularly the EBIT Margin and Tax Burden.

EBIT Margin
The EBIT Margin demonstrated a strong increase from 36.86% in 2021 to 48.01% in 2022, indicating improved operational profitability. However, this margin contracted to 44.83% in 2023 before experiencing a dramatic decline to 2.53% in 2024. A partial recovery to 38.80% is observed in 2025, though it remains below the levels seen in 2021 and 2022. This volatility significantly impacted overall ROE.
Tax Burden
The Tax Burden generally remained relatively stable around 0.86-0.83 between 2021 and 2023. A substantial negative value of -2.16 was recorded in 2024, likely due to tax benefits or adjustments, which temporarily inflated ROE despite the low EBIT Margin. The Tax Burden returned to a more typical level of 0.85 in 2025.
Interest Burden
The Interest Burden remained consistently high, fluctuating minimally between 0.98 and 1.00 throughout the period. A slight decrease to 0.89 in 2024 was observed, followed by a return to 1.00 in 2025. This indicates a consistently high level of interest expense relative to EBIT.
Asset Turnover
Asset Turnover exhibited a consistent downward trend from 0.56 in 2021 to 0.43 in 2023, suggesting decreasing efficiency in utilizing assets to generate revenue. A slight increase to 0.49 in 2024 and a further increase to 0.47 in 2025 indicate a potential stabilization, but the overall trend remains negative. This decline contributed to the lower ROE figures.
Financial Leverage
Financial Leverage remained relatively stable between 1.29 and 1.33 throughout the period, with a slight increase to 1.37 in 2024 and remaining at that level in 2025. This indicates a consistent use of debt financing. The stability of this component suggests that changes in ROE are primarily driven by profitability and efficiency, rather than capital structure.

In summary, the significant fluctuations in ROE are primarily attributable to the volatility of the EBIT Margin, coupled with the unusual Tax Burden in 2024. The declining Asset Turnover also contributed to the overall performance trends. While Financial Leverage remained stable, its consistent level suggests that debt financing is a regular component of the company’s capital structure.


Two-Component Disaggregation of ROA

Vertex Pharmaceuticals Inc., decomposition of ROA

Microsoft Excel
ROA = Net Profit Margin × Asset Turnover
Dec 31, 2025 = ×
Dec 31, 2024 = ×
Dec 31, 2023 = ×
Dec 31, 2022 = ×
Dec 31, 2021 = ×

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The financial performance, as indicated by the two-component disaggregation of Return on Assets (ROA), reveals fluctuating profitability and efficiency levels over the five-year period. A notable divergence in trends is observed between Net Profit Margin and Asset Turnover, ultimately impacting the overall ROA.

Net Profit Margin
The Net Profit Margin demonstrates an initial increase from 30.92% in 2021 to a peak of 37.20% in 2022. This positive trend plateaus in 2023 with a slight decrease to 36.68%. A significant disruption occurs in 2024, with the margin declining sharply to -4.86%, indicating a substantial net loss. A recovery is then evident in 2025, with the margin rebounding to 32.94%, though remaining below the levels seen in 2021-2023.
Asset Turnover
Asset Turnover exhibits a consistent downward trend from 0.56 in 2021 to 0.43 in 2023, suggesting decreasing efficiency in utilizing assets to generate sales. A slight recovery is seen in 2024, with the ratio increasing to 0.49. This upward movement continues modestly in 2025, reaching 0.47, but does not fully offset the prior declines.
Return on Assets (ROA)
The ROA initially mirrors the positive momentum of the Net Profit Margin, increasing from 17.44% in 2021 to 18.30% in 2022. The subsequent decline in Net Profit Margin, coupled with the decreasing Asset Turnover, leads to a reduction in ROA to 15.92% in 2023. The substantial loss reflected in the 2024 Net Profit Margin results in a negative ROA of -2.38%. The ROA partially recovers in 2025 to 15.42%, driven by the improvement in Net Profit Margin, but remains below the 2021 and 2022 levels.

The interplay between profitability and efficiency significantly influences the overall ROA. While the Net Profit Margin initially contributed positively to ROA growth, its dramatic decline in 2024 overwhelmed the stabilizing effect of the Asset Turnover, resulting in a negative ROA. The partial recovery in 2025 suggests a sensitivity of ROA to changes in profitability, with asset utilization playing a secondary, though consistent, role.


Four-Component Disaggregation of ROA

Vertex Pharmaceuticals Inc., decomposition of ROA

Microsoft Excel
ROA = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover
Dec 31, 2025 = × × ×
Dec 31, 2024 = × × ×
Dec 31, 2023 = × × ×
Dec 31, 2022 = × × ×
Dec 31, 2021 = × × ×

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The four-component disaggregation of Return on Assets (ROA) reveals a complex performance pattern over the five-year period. While ROA initially increased, a significant decline occurred in 2024, followed by a partial recovery in 2025. This fluctuation is attributable to shifts in the underlying components of profitability and efficiency.

EBIT Margin
The EBIT Margin demonstrated a strong increase from 36.86% in 2021 to 48.01% in 2022, indicating improved operational profitability. However, this margin decreased to 44.83% in 2023 before experiencing a substantial drop to 2.53% in 2024. A recovery to 38.80% is observed in 2025, though it remains below the levels seen in 2022 and 2021. This volatility suggests potential challenges in maintaining consistent profitability.
Asset Turnover
Asset Turnover exhibited a consistent downward trend from 0.56 in 2021 to 0.43 in 2023, suggesting decreasing efficiency in utilizing assets to generate revenue. A slight increase to 0.49 in 2024 was followed by a further decrease to 0.47 in 2025. This indicates that the company generates less revenue for each dollar of assets held.
Tax Burden
The Tax Burden remained relatively stable around 0.86-0.83 for the period 2021-2023. A significant anomaly occurred in 2024, with a negative Tax Burden of -2.16, potentially indicating tax benefits or adjustments. The Tax Burden returned to 0.85 in 2025, aligning with prior years. This fluctuation significantly impacts net income and, consequently, ROA.
Interest Burden
The Interest Burden remained consistently high, fluctuating minimally between 0.98 and 1.00 throughout the period, with a slight decrease to 0.89 in 2024. This indicates a substantial portion of pre-tax income is allocated to interest expenses, limiting overall profitability.

The decline in ROA in 2024 is primarily driven by the dramatic reduction in the EBIT Margin and, to a lesser extent, the continued decline in Asset Turnover. The negative Tax Burden partially offset this decline, but was not sufficient to prevent an overall decrease in ROA. The partial recovery in ROA in 2025 is linked to the improvement in EBIT Margin, although Asset Turnover remains subdued. The consistently high Interest Burden continues to constrain overall profitability.


Disaggregation of Net Profit Margin

Vertex Pharmaceuticals Inc., decomposition of net profit margin ratio

Microsoft Excel
Net Profit Margin = Tax Burden × Interest Burden × EBIT Margin
Dec 31, 2025 = × ×
Dec 31, 2024 = × ×
Dec 31, 2023 = × ×
Dec 31, 2022 = × ×
Dec 31, 2021 = × ×

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The financial performance, as indicated by the provided metrics, exhibits notable fluctuations over the five-year period. A significant divergence emerges in 2024, impacting profitability metrics. The analysis focuses on the disaggregation of net profit margin through examination of the tax burden, interest burden, and EBIT margin.

Net Profit Margin
Net profit margin demonstrates an initial increase from 30.92% in 2021 to 37.20% in 2022, followed by a slight decrease to 36.68% in 2023. However, a substantial decline is observed in 2024, resulting in a negative margin of -4.86%. A partial recovery is then seen in 2025, with the margin rising to 32.94% but remaining below the levels observed in the earlier years.
EBIT Margin
The EBIT margin generally tracked the net profit margin trend until 2024. It increased from 36.86% in 2021 to 48.01% in 2022, then decreased to 44.83% in 2023. The most dramatic shift occurs in 2024, where the EBIT margin falls sharply to 2.53%. A considerable increase is then noted in 2025, reaching 38.80%, though still below the 2022 peak.
Tax Burden
The tax burden remained relatively stable between 2021 and 2023, fluctuating between 0.78 and 0.86. A significant outlier is observed in 2024, with a tax burden of -2.16, suggesting a substantial tax benefit or credit was realized. The tax burden returns to a value of 0.85 in 2025, aligning with the prior trend.
Interest Burden
The interest burden remained consistently high, hovering around 0.98 to 1.00 throughout the period, with a slight decrease to 0.89 in 2024 before returning to 1.00 in 2025. This indicates a consistently significant portion of earnings is allocated to interest expenses.

The substantial decline in net profit margin and EBIT margin in 2024 appears to be partially offset by a negative tax burden. However, the underlying operational performance, as indicated by the EBIT margin, experienced a significant downturn. The consistent interest burden suggests limited changes in the company’s debt structure or financing costs. The recovery observed in 2025, while positive, does not fully restore the profitability levels seen in 2021-2023.